CorMedix
CorMedix is a specialty pharmaceutical company that commercializes DefenCath, the only FDA-approved antimicrobial catheter lock solution for hemodialysis patients, and a portfolio of acquired hospital anti-infective products targeting US hospitals, dialysis providers, and hematology/oncology centers.
- Company typePublic
- Founded2006
- HeadquartersBridgewater, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What CorMedix does
CorMedix Inc. is a publicly traded (NASDAQ: CRMD) specialty pharmaceutical company founded in 2006 and headquartered in Berkeley Heights, New Jersey, that develops and commercializes therapeutic products for life-threatening conditions in institutional care settings, with a portfolio centered on anti-infectives for cardiac, renal, and infectious disease indications. Its core asset, DefenCath (taurolidine and heparin), is the only FDA-approved antimicrobial catheter lock solution indicated to reduce catheter-related bloodstream infections (CRBSIs) in adult hemodialysis patients with central venous catheters; the product is built on a proprietary taurolidine platform whose mechanism disrupts bacterial cell walls, prevents biofilm formation by destroying fimbriae, and neutralizes bacterial exotoxins and endotoxins, and is not susceptible to known resistance mechanisms. Following the August 2025 acquisition of Melinta Therapeutics for $300 million, CorMedix operates a diversified specialty anti-infective portfolio that also includes REZZAYO (rezafungin, an echinocandin approved for candidemia/invasive candidiasis with a Phase III prophylaxis indication pending), MINOCIN, VABOMERE, ORBACTIV, BAXDELA, KIMYRSA, and TOPROL-XL, all commercialized through a direct field-based sales organization targeting hospitals, outpatient dialysis providers, infusion clinics, and hematology/oncology centers in the United States. CorMedix generated $311.7M in reported FY2025 revenue and $127.4M in Q1 2026 revenue, with FY2026 guidance of $325-345M; revenue is generated through institutional pharmaceutical product sales subject to CMS reimbursement dynamics including a TDAPA-to-post-TDAPA add-on adjustment transition for DefenCath effective July 1, 2026.
CorMedix firmographics
Firmographics- Name
- CorMedix
- Legal name
- CorMedix Inc.
- Website
- https://cormedix.com
- Company type
- Public
- Founded year
- 2006
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- CorMedix is a specialty pharmaceutical company that commercializes DefenCath, the only FDA-approved antimicrobial catheter lock solution for hemodialysis patients, and a portfolio of acquired hospital anti-infective products targeting US hospitals, dialysis providers, and hematology/oncology centers.
- Ownership category
- akta.pro rank
CorMedix industry classification
Industry- Product category
- Specialty Pharmaceuticals
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Infusion Sets, Catheters & Pump Consumables (HLAHAIAH)
- akta.pro secondary industry
- Vascular Access Devices (AV Grafts, Catheters, Fistula Accessories) (HLAHAKAE)
Keywords
Where CorMedix is headquartered
LocationHeadquarters
- HQ city
- Bridgewater
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
CorMedix business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain
Revenue model
- DefenCath product sales: Revenue generated from sales of DefenCath (taurolidine and heparin) for prevention of catheter-related bloodstream infections in adult hemodialysis patients. DefenCath contributed $97.5 million in Q1 2026 and $91.2 million in Q4 2025. Full-year 2025 DefenCath net sales were $258.8 million.
- Melinta anti-infective portfolio: Revenue from the acquired Melinta Therapeutics portfolio including REZZAYO, MINOCIN, VABOMERE, ORBACTIV, BAXDELA, KIMYRSA, and TOPROL-XL. The Melinta portfolio contributed $29.9 million in Q1 2026 and $37.4 million in Q4 2025, with pro forma full-year 2025 contribution of approximately $140 million.
- REZZAYO future revenue (pending FDA approval for prophylaxis): Revenue anticipated from expanded REZZAYO indication for prophylaxis of invasive fungal diseases, pending FDA sNDA submission in 2H26 following positive Phase III ReSPECT topline results. CorMedix estimates potential US market opportunity exceeding $2 billion for REZZAYO in prophylaxis.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels4 records
CorMedix product offering
Product offeringCore offering
CorMedix develops and commercializes specialty pharmaceutical products for life-threatening cardiac, renal, and infectious diseases. The company's leading product, DefenCath, is an FDA-approved antimicrobial catheter lock solution (taurolidine and heparin) used to reduce catheter-related bloodstream infections in patients with central venous catheters for hemodialysis. Its broader commercial portfolio includes anti-infective and cardiovascular products such as REZZAYO, MINOCIN for Injection, VABOMERE, ORBACTIV/KIMYRSA, BAXDELA, and TOPROL-XL.
Product overview
CorMedix is a diversified specialty biopharmaceutical company commercializing therapeutic products for life-threatening conditions in institutional care settings. The portfolio centers on DefenCath (taurolidine and heparin), an FDA-approved catheter lock solution for preventing bloodstream infections in hemodialysis patients, supplemented by an acquired portfolio of anti-infective products from Melinta Therapeutics including REZZAYO (rezafungin), MINOCIN, VABOMERE, ORBACTIV, BAXDELA, KIMYRSA, and TOPROL-XL. The company is also advancing pipeline programs including REZZAYO for fungal prophylaxis indication and DefenCath for total parenteral nutrition applications.
Differentiator
Problem solved
Functional benefit
Brands
- DefenCath: FDA-approved antimicrobial catheter lock solution (taurolidine and heparin) for preventing catheter-related bloodstream infections in hemodialysis patients
- REZZAYO
- MINOCIN
- VABOMERE
- ORBACTIV
- BAXDELA
- KIMYRSA
- TOPROL-XL
Products and services
- DefenCath DefenCath is an FDA-approved antimicrobial catheter lock solution combining taurolidine and heparin, indicated to reduce the incidence of catheter-related bloodstream infections (CRBSIs) in adult patients with central venous catheters for hemodialysis. It is sold to hospitals, dialysis centers, and specialty distributors and used by nephrologists, infectious disease specialists, and vascular access teams.
- REZZAYO (rezafungin) REZZAYO is an antifungal (rezafungin) product in CorMedix's anti-infective portfolio for the treatment of serious fungal infections, sold through hospital and specialty channels.
- MINOCIN (minocycline) for Injection MINOCIN for Injection is a tetracycline-class antibiotic indicated for the treatment of infections caused by susceptible strains of designated microorganisms, distributed to hospitals and specialty care settings.
- VABOMERE (meropenem and vaborbactam) VABOMERE is a combination antibacterial (meropenem and vaborbactam) indicated for the treatment of complicated urinary tract infections and other serious bacterial infections, sold to hospitals and infectious disease specialists.
- ORBACTIV (oritavancin) ORBACTIV is an antibacterial (oritavancin) used for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible Gram-positive organisms, distributed through hospital and specialty pharmacy channels.
- KIMYRSA (oritavancin) KIMYRSA is an oritavancin-based antibacterial offering a shorter infusion option for acute bacterial skin and skin structure infections, sold via hospital outpatient and specialty channels.
- BAXDELA (delafloxacin) BAXDELA is a fluoroquinolone antibacterial (delafloxacin) indicated for the treatment of acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia, sold to hospitals and specialty providers.
- TOPROL-XL (metoprolol succinate) TOPROL-XL is a cardiovascular product (metoprolol succinate extended-release) indicated for the treatment of angina, heart failure, and hypertension, part of CorMedix's broader commercial portfolio serving cardiac patients.
Quantifiable outcome
- 71% reduction in catheter-related bloodstream infection risk (CRBSI) in hemodialysis patients (LOCK-IT-100 Phase III, p=0.0006)
- +6 more outcomes
Companies that use CorMedix
Customer profileNamed customers2 records
Segments4 records
Ideal customer profiles1 record
CorMedix technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
CorMedix partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered minor and core.
- TalpheraminorCorMedix made a strategic investment in Talphera and has the right to negotiate an acquisition of Talphera. Talphera's Niyad drug is expected to receive potential PMA approval in late 2026, with the NEPHRO study expected to complete in H1 2026.
- Melinta TherapeuticscoreCorMedix acquired Melinta Therapeutics in a deal valued at approximately $300 million in cash and stock in August 2025, transforming CorMedix into a diversified specialty pharmaceutical company with six approved anti-infective products. Melinta is now a wholly owned subsidiary of CorMedix and adds approximately $140 million in pro forma revenue to the combined entity.
- POETIC (Pediatric Oncology Therapeutic Investigators Consortium)minorCollaboration with POETIC to evaluate a novel formulation of taurolidine (CMDX-001) as investigational therapy for rare pediatric cancers including neuroblastoma and osteosarcoma. The collaboration advances preclinical studies and will determine clinical strategy once in vivo proof-of-concept is achieved.
- MundipharmacoreMundipharma is the global sponsor of the Phase III ReSPECT clinical trial evaluating REZZAYO for prophylaxis of invasive fungal diseases. Mundipharma has commercial rights to rezafungin outside the United States and partnered with Melinta Therapeutics (a CorMedix subsidiary) for US distribution. The companies jointly announced positive topline results in April 2026 and plan to submit an sNDA to the FDA in 2H26.
Scale indicators14 records
Recent moves7 records
Expansion highlights6 records
CorMedix competitors and assessment
Company assessmentDirect peers
- Citius Pharmaceuticals: Late-stage specialty biopharma focused on anti-infective and oncology assets, including an investigational catheter lock solution (Mino-Lok) directly competing with DefenCath in the catheter-related bloodstream infection space.
- ANI Pharmaceuticals: Specialty pharmaceutical company that develops, manufactures, and markets branded and generic prescription pharmaceuticals, including injectable anti-infectives — closely comparable to CorMedix's Melinta portfolio in hospital and acute care channels.
- Eagle Pharmaceuticals: Specialty pharma focused on injectable and hospital-based products, including anti-infectives and oncology supportive care, with a similar hospital sales force model and focus on differentiated reformulations — a direct analog to CorMedix's commercial approach.
- Melinta Therapeutics (subsidiary): Now a wholly-owned CorMedix subsidiary post the August 2025 acquisition; historically a direct peer as a hospital-focused anti-infective company commercializing MINOCIN, VABOMERE, ORBACTIV, BAXDELA, KIMYRSA, and ORBACTIV — effectively CorMedix's closest historical peer.
- Paratek Pharmaceuticals: Commercial-stage anti-infective company (acquired by Novo Holdings in 2023) that developed and commercialized omadacycline and other differentiated hospital antibiotics, directly comparable to CorMedix's Melinta portfolio strategy.
Emerging players
- Theratechnologies: Specialty biopharma commercializing hospital and specialty therapeutics with similar institutional sales channels. Comparable in size and development stage and competes in similar end markets.
- Harrow Health: Specialty pharmaceutical company focused on branded ophthalmic and hospital products, sharing a comparable niche-specialty commercial model and a portfolio-acquisition growth strategy similar to CorMedix's Melinta playbook.
- Nabriva Therapeutics: Specialty biopharma commercializing hospital antibiotics for resistant infections, sharing CorMedix's anti-infective focus and hospital channel orientation at a smaller commercial scale.
Broad incumbents
- Becton, Dickinson and Company (BD): Global medical device incumbent with a leading vascular access and drug delivery portfolio. While BD does not market a competing catheter lock solution, it is the dominant supplier of central venous catheters and infusion sets into which DefenCath is administered, making it a critical channel partner and adjacent incumbent.
- ICU Medical: Medical device company specializing in IV therapy, infusion sets, and catheter-related products. Operates adjacent to CorMedix in the vascular access ecosystem, particularly relevant for DefenCath's deployment in hospital and dialysis settings.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
CorMedix social profiles
Digital presenceCorMedix compliance and trust
Trust signalCompliance2 records
CorMedix financial estimates
Financial estimateRevenue estimate
Valuation estimate
CorMedix leadership team
Management profileNumber of profiles
Profiles6 records
CorMedix subsidiaries and ownership
Company hierarchySubsidiaries1 record
CorMedix funding detail
Funding detailFunding overview
Funding rounds5 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
CorMedix M&A and investment
M&A and investmentM&A1 record
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about CorMedix
What does CorMedix do?
CorMedix develops and commercializes specialty pharmaceutical products for life-threatening cardiac, renal, and infectious diseases. The company's leading product, DefenCath, is an FDA-approved antimicrobial catheter lock solution (taurolidine and heparin) used to reduce catheter-related bloodstream infections in patients with central venous catheters for hemodialysis. Its broader commercial portfolio includes anti-infective and cardiovascular products such as REZZAYO, MINOCIN for Injection, VABOMERE, ORBACTIV/KIMYRSA, BAXDELA, and TOPROL-XL.
Is CorMedix a public or private company?
CorMedix is a public company. It is classified as public and is currently operating.
When was CorMedix founded?
CorMedix was founded in 2006. It employs 51 to 100 people.
Where is CorMedix based?
CorMedix is headquartered in Bridgewater, United States, in the North America region.
How does CorMedix make money?
Three revenue lines are on record. DefenCath product sales are the primary driver. The others are melinta anti-infective portfolio and REZZAYO future revenue (pending FDA approval for prophylaxis).
Who are CorMedix's main competitors?
Direct peers on record are Citius Pharmaceuticals, ANI Pharmaceuticals, Eagle Pharmaceuticals, Melinta Therapeutics (subsidiary) and Paratek Pharmaceuticals. Emerging players are Theratechnologies, Harrow Health and Nabriva Therapeutics. Broad incumbents are Becton, Dickinson and Company (BD) and ICU Medical.
Does CorMedix have an API?
No public API is recorded for CorMedix.
What industry is CorMedix in?
CorMedix's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAHAIAH, Infusion Sets, Catheters & Pump Consumables, with a secondary code of HLAHAKAE, Vascular Access Devices (AV Grafts, Catheters, Fistula Accessories). Its NAICS code is 3254 and its SIC code is 2834.